NCT06038526 2026-02-19
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Mario Negri Institute for Pharmacological Research
Novartis